Enanta Pharmaceuticals (ENTA) Interest Expenses (2012 - 2026)

Enanta Pharmaceuticals' Interest Expenses history runs 15 years deep, the most recent figure standing at $7.7 million for Q1 2026.

• Quarterly Interest Expenses rose 348.72% year-over-year to $7.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.7 million (down 80.73% YoY) and the FY2025 annual result came in at $142.2 million, up 1114.63% from the prior year.
• Interest Expenses was $7.7 million for Q1 2026 at Enanta Pharmaceuticals, up from $3.1 million in the prior quarter.
• Across five years, Interest Expenses topped out at $113.9 million in Q2 2022 and bottomed at -$10000.0 in Q3 2023.
• A 5-year average of $26.8 million and a median of $7.7 million in 2026 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2023 — Interest Expenses tumbled 98.25% — and 2024, when it surged 32630.0%.
• Enanta Pharmaceuticals' Interest Expenses stood at $17.6 million in 2022, then slumped by 80.5% to $3.4 million in 2023, then declined by 12.58% to $3.0 million in 2024, then climbed by 2.49% to $3.1 million in 2025, then soared by 149.46% to $7.7 million in 2026.
• Business Quant data shows ENTA's Interest Expenses at $7.7 million in Q1 2026, $3.1 million in Q4 2025, and $9.3 million in Q3 2025.